{"id":"https://openalex.org/W2980047232","doi":"https://doi.org/10.1182/blood.v114.22.756.756","title":"Long-Term Follow up and Optimized Dosing Regimen of INCB018424 in Patients with Myelofibrosis: Durable Clinical, Functional and Symptomatic Responses with Improved Hematological Safety.","display_name":"Long-Term Follow up and Optimized Dosing Regimen of INCB018424 in Patients with Myelofibrosis: Durable Clinical, Functional and Symptomatic Responses with Improved Hematological Safety.","publication_year":2009,"publication_date":"2009-11-20","ids":{"openalex":"https://openalex.org/W2980047232","doi":"https://doi.org/10.1182/blood.v114.22.756.756","mag":"2980047232"},"language":"en","primary_location":{"id":"doi:10.1182/blood.v114.22.756.756","doi":"https://doi.org/10.1182/blood.v114.22.756.756","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v114.22.756.756","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5085521139","display_name":"Sr\u0111an Verstov\u0161ek","orcid":"https://orcid.org/0000-0002-6912-8569","observed_orcids":["https://orcid.org/0000-0002-6912-8569"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Srdan Verstovsek","raw_affiliation_strings":["Department of Leukemia, M.D. Anderson Cancer Center, Houston, TX, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Leukemia, M.D. Anderson Cancer Center, Houston, TX, USA,","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090435894","display_name":"Hagop M. Kantarjian","orcid":"https://orcid.org/0000-0002-1908-3307","observed_orcids":["https://orcid.org/0000-0002-1908-3307"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hagop Kantarjian","raw_affiliation_strings":["Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA,","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039057642","display_name":"Ruben A. Mesa","orcid":"https://orcid.org/0000-0001-5880-7972","observed_orcids":["https://orcid.org/0000-0001-5880-7972"]},"institutions":[{"id":"https://openalex.org/I4210125099","display_name":"Mayo Clinic in Arizona","ror":"https://ror.org/03jp40720","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723","https://openalex.org/I4210125099"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ruben A. Mesa","raw_affiliation_strings":["Mayo Clinic, Scottsdale, AZ, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mayo Clinic, Scottsdale, AZ, USA,","institution_ids":["https://openalex.org/I4210125099"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015101485","display_name":"J\u00f6rge E. Cortes","orcid":"https://orcid.org/0000-0002-8636-1071","observed_orcids":["https://orcid.org/0000-0002-8636-1071"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Jorge Cortes-Franco","raw_affiliation_strings":["Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA,","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024612499","display_name":"Animesh Dev Pardanani","orcid":"https://orcid.org/0000-0002-9084-4148","observed_orcids":["https://orcid.org/0000-0002-9084-4148"]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Animesh D. Pardanani","raw_affiliation_strings":["Hematology, Mayo Clinic, Rochester, MN, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hematology, Mayo Clinic, Rochester, MN, USA,","institution_ids":["https://openalex.org/I1330342723"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038307470","display_name":"Deborah Ann Thomas","orcid":"https://orcid.org/0000-0002-2656-343X","observed_orcids":["https://orcid.org/0000-0002-2656-343X"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Deborah A. Thomas","raw_affiliation_strings":["Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA,","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084290698","display_name":"Zeev E. Estrov","orcid":"https://orcid.org/0000-0002-1623-3613","observed_orcids":["https://orcid.org/0000-0002-1623-3613"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Zeev Estrov","raw_affiliation_strings":["Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA,","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110170216","display_name":"Edward C. Bradley","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I924451375","display_name":"Incyte (United States)","ror":"https://ror.org/00cvzzg84","country_code":"US","type":"company","lineage":["https://openalex.org/I924451375"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Edward C Bradley","raw_affiliation_strings":["Incyte Corporation, Wilmington, DE, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Incyte Corporation, Wilmington, DE, USA,","institution_ids":["https://openalex.org/I924451375"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111483733","display_name":"Susan Erickson\u2010Viitanen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I924451375","display_name":"Incyte (United States)","ror":"https://ror.org/00cvzzg84","country_code":"US","type":"company","lineage":["https://openalex.org/I924451375"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Susan Erickson-Viitanen","raw_affiliation_strings":["Incyte Co., Wilmington, DE,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Incyte Co., Wilmington, DE,","institution_ids":["https://openalex.org/I924451375"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046355139","display_name":"Kris Vaddi","orcid":"https://orcid.org/0009-0009-8581-6511","observed_orcids":["https://orcid.org/0009-0009-8581-6511"]},"institutions":[{"id":"https://openalex.org/I924451375","display_name":"Incyte (United States)","ror":"https://ror.org/00cvzzg84","country_code":"US","type":"company","lineage":["https://openalex.org/I924451375"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Kris Vaddi","raw_affiliation_strings":["Incyte Corporation, Wilmington, DE, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Incyte Corporation, Wilmington, DE, USA,","institution_ids":["https://openalex.org/I924451375"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Richard Levy","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I924451375","display_name":"Incyte (United States)","ror":"https://ror.org/00cvzzg84","country_code":"US","type":"company","lineage":["https://openalex.org/I924451375"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Richard Levy","raw_affiliation_strings":["Incyte, Wilmington, DE, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Incyte, Wilmington, DE, USA","institution_ids":["https://openalex.org/I924451375"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5016216479","display_name":"Ayalew Tefferi","orcid":"https://orcid.org/0000-0003-4605-3821","observed_orcids":["https://orcid.org/0000-0003-4605-3821"]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ayalew Tefferi","raw_affiliation_strings":["Hematology, Mayo Clinic, Rochester, MN, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hematology, Mayo Clinic, Rochester, MN, USA,","institution_ids":["https://openalex.org/I1330342723"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":4,"corresponding_author_ids":["https://openalex.org/A5015101485","https://openalex.org/A5046355139","https://openalex.org/A5110170216","https://openalex.org/A5111483733"],"corresponding_institution_ids":["https://openalex.org/I1343551460","https://openalex.org/I924451375"],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":2.5671,"has_fulltext":false,"cited_by_count":18,"citation_normalized_percentile":{"value":0.89494787,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":93},"biblio":{"volume":"114","issue":"22","first_page":"756","last_page":"756"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11628","display_name":"Myeloproliferative Neoplasms: Diagnosis and Treatment","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11628","display_name":"Myeloproliferative Neoplasms: Diagnosis and Treatment","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/myelofibrosis","display_name":"myelofibrosis","score":0.968999981880188},{"id":"https://openalex.org/keywords/jak1-2-inhibitor","display_name":"JAK1/2 inhibitor","score":0.9409999847412109},{"id":"https://openalex.org/keywords/dose-optimization","display_name":"dose optimization","score":0.6890000104904175},{"id":"https://openalex.org/keywords/long-term-follow-up","display_name":"long-term follow-up","score":0.7450000047683716},{"id":"https://openalex.org/keywords/splenomegaly","display_name":"splenomegaly","score":0.7929999828338623},{"id":"https://openalex.org/keywords/spleen-volume","display_name":"spleen volume","score":0.7490000128746033},{"id":"https://openalex.org/keywords/thrombocytopenia","display_name":"thrombocytopenia","score":0.8119999766349792},{"id":"https://openalex.org/keywords/hematological-safety","display_name":"hematological safety","score":0.6439999938011169},{"id":"https://openalex.org/keywords/exercise-capacity","display_name":"exercise capacity","score":0.7129999995231628},{"id":"https://openalex.org/keywords/6-minute-walk-test","display_name":"6-minute walk test","score":0.8299999833106995},{"id":"https://openalex.org/keywords/progression-to-acute-myeloid-leukemia","display_name":"progression to acute myeloid leukemia","score":0.75},{"id":"https://openalex.org/keywords/myeloproliferative-neoplasms","display_name":"myeloproliferative neoplasms","score":0.9049999713897705},{"id":"https://openalex.org/keywords/jak2-v617f-mutation","display_name":"JAK2 V617F mutation","score":0.7549999952316284},{"id":"https://openalex.org/keywords/interleukin-6","display_name":"interleukin-6","score":0.5220000147819519},{"id":"https://openalex.org/keywords/myelosuppression","display_name":"myelosuppression","score":0.5910000205039978}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8459327220916748},{"id":"https://openalex.org/C2780076729","wikidata":"https://www.wikidata.org/wiki/Q1752571","display_name":"Myelofibrosis","level":3,"score":0.8420424461364746},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.7088925838470459},{"id":"https://openalex.org/C2781413609","wikidata":"https://www.wikidata.org/wiki/Q7308373","display_name":"Regimen","level":2,"score":0.6608121991157532},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.630233645439148},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.4850108325481415},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.48445606231689453},{"id":"https://openalex.org/C2776112149","wikidata":"https://www.wikidata.org/wiki/Q7383611","display_name":"Ruxolitinib","level":4,"score":0.46775221824645996},{"id":"https://openalex.org/C141341695","wikidata":"https://www.wikidata.org/wiki/Q2368661","display_name":"Surrogate endpoint","level":2,"score":0.4634212553501129},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.4408726394176483},{"id":"https://openalex.org/C2780007613","wikidata":"https://www.wikidata.org/wiki/Q546523","display_name":"Bone marrow","level":2,"score":0.36541399359703064},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.32745909690856934},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.32019782066345215}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood.v114.22.756.756","doi":"https://doi.org/10.1182/blood.v114.22.756.756","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v114.22.756.756","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2549440460","https://openalex.org/W2123633897","https://openalex.org/W2197956845","https://openalex.org/W2588005189","https://openalex.org/W2536171864","https://openalex.org/W1986595955","https://openalex.org/W2020412873","https://openalex.org/W2946741440","https://openalex.org/W4253502065","https://openalex.org/W218273434"],"abstract_inverted_index":{"Abstract":[0,1],"756":[2],"Background:":[3],"Myelofibrosis":[4],"(MF)":[5],"is":[6,18,42,272,315,603],"the":[7,84,107,110,215,226,248,274,320,329,360,511,607],"most":[8,254,347],"serious":[9],"of":[10,35,58,66,70,91,112,134,149,158,163,186,207,220,222,228,231,240,251,260,304,307,311,319,345,362,394,405,408,420,463,474,481,505,519,569,598,610,613],"chronic":[11],"myeloproliferative":[12],"neoplasms":[13],"(MPNs)":[14],"for":[15],"which":[16,271],"there":[17],"no":[19],"approved":[20],"therapy.":[21,208,544,615],"Exaggerated":[22],"JAK2":[23],"signaling,":[24],"either":[25],"by":[26,141,423,444,606],"gain-of-function":[27],"mutations":[28],"(eg,":[29,39],"JAK2V617F)":[30],"or":[31,101,302,305,333,353,471],"high":[32],"circulating":[33],"levels":[34],"JAK1/2":[36],"activating":[37],"cytokines":[38],"interleukin":[40],"[IL]-6),":[41],"believed":[43],"to":[44,153,265,288,298,327,351,370,415,543,589],"play":[45],"a":[46,54,73,132,172,183,194,482,527,590],"key":[47,488],"role":[48],"in":[49,72,77,89,106,151,214,268,291,427,454,510,523,532,553,572,579,600],"MPN":[50],"pathogenesis.":[51],"INCB018424":[52,570],"(424),":[53],"selective":[55],"oral":[56],"inhibitor":[57],"JAK1/2,":[59],"has":[60],"demonstrated":[61],"clinical":[62,417],"benefits":[63,578],"including":[64,535],"reduction":[65,381,413,422,480,509,531],"splenomegaly":[67],"and":[68,128,146,204,225,253,294,309,336,342,389,466,478,497,503,516,529,539,559,576,596],"improvement":[69,418],"symptoms":[71,168,310,489,524],"Phase":[74],"I/II":[75],"trial":[76],"MF":[78,103,166,312,433,580,601],"patients.":[79],"Thrombocytopenia":[80],"was":[81,122,139,169,191,382,499,548],"identified":[82],"as":[83,384,386],"dose":[85,119,331,338,372],"limiting":[86],"toxicity":[87],"occurring":[88],"30%":[90],"patients":[92,211,236,255,348,409,434,506,581,602],"at":[93,143,200,430,439],"25mg":[94],"BID.":[95,355],"Methods:":[96],"Patients":[97],"with":[98,193,217,451,458,526,550,582],"primary,":[99],"post-PV":[100],"post-ET":[102],"were":[104,212,349],"enrolled":[105,213],"study.":[108],"Following":[109],"characterization":[111],"multiple":[113],"dosing":[114,321,377,567],"regimens,":[115],"an":[116,155,375,583],"individually":[117],"optimized":[118,350,376,566],"regimen":[120,322,568],"strategy":[121],"developed,":[123],"based":[124,277,486],"on":[125,165,257,278,487],"available":[126],"efficacy":[127,369,597],"safety":[129,586],"data.":[130],"In":[131],"subset":[133],"patients,":[135,270,293],"spleen":[136,159,379,428,546],"volume":[137,380,429],"change":[138],"measured":[140],"MRI":[142],"1,":[144,202],"3":[145,203,269],"6":[147,205,392,401,472,517],"months":[148,206,344,473,518],"treatment":[150,221,252],"order":[152],"establish":[154],"objective":[156],"measure":[157],"response.":[160],"The":[161],"impact":[162],"424":[164,289,452,599,614],"associated":[167,549],"assessed":[170,192],"using":[171],"validated":[173],"instrument,":[174],"MFSAF":[175],"(Mesa":[176],"et":[177,282],"al.,":[178,283],"Leukemia":[179],"Research":[180,619],"2009).":[181],"As":[182],"surrogate":[184],"marker":[185],"functional":[187,577],"benefit,":[188],"exercise":[189,437,557],"capacity":[190,438],"standardized":[195],"6-minute":[196],"walk":[197],"test":[198],"(6MWT)":[199],"baseline,":[201],"Results:":[209],"155":[210,261],"study,":[216],"median":[218,398,459],"duration":[219,227,250],"1+":[223],"years":[224,234],"drug":[229],"exposure":[230],">150":[232],"patient":[233],"(76":[235],"received":[237],">1":[238,611],"year":[239],"therapy).":[241],"Clinical":[242],"responses":[243],"have":[244,435],"been":[245],"maintained":[246],"over":[247,391],"entire":[249],"remain":[256],"therapy":[258,314,395],"(115":[259],"patients;":[262],"74%).":[263],"Progression":[264],"AML":[266],"occurred":[267,290],"below":[273],"expected":[275],"frequency":[276],"published":[279],"data":[280,609],"(Barosi":[281],"Blood":[284],"2007).":[285],"SAEs":[286],"related":[287,297],"12":[292],"are":[295],"generally":[296],"bone":[299],"marrow":[300],"suppression":[301],"return":[303],"exacerbation":[306],"signs":[308],"when":[313],"discontinued.":[316],"Further":[317],"optimization":[318],"utilized":[323],"baseline":[324,426,440,462],"platelet":[325],"count":[326],"determine":[328],"starting":[330],"(10":[332],"15mg":[334],"BID)":[335],"allowed":[337],"titration":[339],"after":[340,400,469],"1":[341,387,515],"2":[343],"therapy;":[346],"15":[352],"20mg":[354],"This":[356],"approach":[357],"significantly":[358],"reduced":[359,560],"incidence":[361],"thrombocytopenia":[363],"(<5%,":[364],"N=35),":[365],"while":[366],"providing":[367],"equivalent":[368],"higher":[371],"regimens.":[373],"With":[374],"regimen,":[378],"evident":[383],"early":[385],"month,":[388],"durable":[390,479],"months,":[393,402],"(33":[396],"%":[397,502],"decrease":[399],"N=23).":[403],"Eleven":[404],"23":[406],"(48%)":[407],"achieved":[410],"\u2265":[411],"35%":[412],"(equivalent":[414],"IWG":[416],"criteria":[419],"50%":[421,508],"palpation)":[424],"from":[425,461],"month":[431],"6.":[432],"impaired":[436],"(decreased":[441],"6MWT":[442,456],"performance":[443],"60-90":[445],"meters":[446,468],"vs.":[447],"age-matched":[448],"controls).":[449],"Treatment":[450],"resulted":[453,571],"improved":[455,584],"performance,":[457],"increase":[460],"33,":[464],"58":[465],"70":[467],"1,3":[470],"therapy,":[475],"respectively.":[476],"Rapid":[477],"total":[483,512,554],"symptom":[484,555],"score":[485,513],"(fatigue,":[490],"abdominal":[491],"discomfort/pain,":[492],"bone/muscle":[493],"pain,":[494],"night":[495],"sweats":[496],"pruritus)":[498],"noted":[500],"(51":[501],"58%":[504],"achieving":[507],"following":[514],"treatment,":[520],"respectively).":[521],"Improvement":[522],"coincided":[525],"rapid":[528],"sustained":[530,573],"pro-inflammatory":[533],"cytokines,":[534],"IL-1b,":[536],"IL-1ra,":[537],"IL-6":[538],"TNFa,":[540],"without":[541],"tachyphylaxis":[542],"Finally,":[545],"response":[547],"greater":[551],"improvements":[552],"score,":[556],"capacity,":[558],"fatigue":[561],"(see":[562],"Table).":[563],"Conclusion:":[564],"An":[565],"clinical,":[574],"symptomatic":[575],"hematological":[585],"profile":[587],"compared":[588],"25":[591],"mg":[592],"BID":[593],"regimen.":[594],"Safety":[595],"further":[604],"supported":[605],"follow-up":[608],"yr":[612],"Disclosures:":[616],"Verstovsek:":[617],"Incyte:":[618],"Funding.":[620],"Bradley:Incyte":[621],"Corporation:":[622,627,632,637],"Employment,":[623,628,633,638],"Equity":[624,629,634,639],"Ownership.":[625,630,635,640],"Erickson-Viitanen:Incyte":[626],"Vaddi:Incyte":[631],"Levy:Incyte":[636]},"counts_by_year":[{"year":2013,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2019-10-18T00:00:00"}